Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04803877 · ClinicalTrials.gov registry record · Phase 2
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
A Phase 2 study of Osteosarcoma and Osteosarcoma Recurrent, sponsored by Sarcoma Alliance for Research through Collaboration.
- Active
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 8
- Study locations
NCT04803877 is a Phase 2 study of Osteosarcoma and Osteosarcoma Recurrent that is active but no longer recruiting, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 48 participants, below the 301-participant average among 46 other Osteosarcoma trials with a reported enrollment target (84% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT04803877, a Phase 2 study of Osteosarcoma and Osteosarcoma Recurrent, is active but no longer recruiting, sponsored by Sarcoma Alliance for Research through Collaboration.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 8
- Study locations
Study Summary
A phase 2 study of regorafenib in combination with nivolumab in patients with refractory or recurrent osteosarcoma.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Regorafenib 40 MG
- DRUG Regorafenib 20MG
Study Locations (8)
California
- Children's Hospital of Los Angeles - Los Angeles
Florida
- University of Miami - Miami
Maryland
- Johns Hopkins - Baltimore
Michigan
- University of Michigan - Ann Arbor
Minnesota
- University of Minnesota - Minneapolis
Ohio
- Cincinnati Children's - Cincinnati
Oregon
- Oregon Health and Sciences University - Portland
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2021-06-04 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04803877
The ClinicalTrials.gov registry entry for NCT04803877 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 301-participant average among 46 other Osteosarcoma trials with a reported enrollment target (84% lower). The listed sponsor is Sarcoma Alliance for Research through Collaboration, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Osteosarcoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT04803877 reports 8 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT04803877 about?
NCT04803877 is a clinical study titled "SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma". A phase 2 study of regorafenib in combination with nivolumab in patients with refractory or recurrent osteosarcoma.
What is the current status of trial NCT04803877?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2021-06-04. Estimated completion is 2026-06.
What conditions does trial NCT04803877 study?
This clinical trial studies the following conditions: Osteosarcoma, Osteosarcoma Recurrent, Osteosarcoma in Children, Osteosarcoma Metastatic.
What interventions are being tested in trial NCT04803877?
The interventions under investigation include: Nivolumab (DRUG), Regorafenib 40 MG (DRUG), Regorafenib 20MG (DRUG).
Who is sponsoring clinical trial NCT04803877?
This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04803877 being conducted?
This trial has 8 study locations across California, Florida, Maryland, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
RECRUITING · Phase 2
-
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
RECRUITING · Phase 2
-
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Olaparib With Ceralasertib in Recurrent Osteosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.